All
Drug approvals give boost to armamentarium for treating AKs, BCCs
April 1st 2012The hot topics of discussion at Maui Derm 2012 were January’s Food and Drug Administration approval of two innovative products in the cutaneous oncology arena: Picato (ingenol mebutate, LEO Pharma) 0.015 percent gel and 0.05 percent gel for the treatment of actinic keratoses (AKs) and Erivedge (vismodegib, Genentech) for the treatment of advanced basal cell carcinoma. At MauiDerm I discussed the data on Picato and Keith Flaherty, M.D., an oncologist from Massachusetts General Hospital, discussed Erivedge.
Quick tips: Dermatologists offer assorted array of practical pearls
April 1st 2012Implementing a few simple ideas in clinical practice can have a significant impact in terms of saving time, saving money or improving patient outcomes. During a session at the 2011 Fall Clinical Dermatology Conference, members of the faculty offered a few personal pearls, each so easy and straightforward they could be encapsulated in a one-minute description.
Next chapter: Retired Naples derm creates clinic for working poor
March 16th 2012William Lascheid, M.D., was in his early 70s when he and his wife, Nancy, retired from four decades of dermatology practice. The couple lived in the lap of retirement luxury in Naples, Fla., and had dreamed about the days when they’d be free to sleep in and spend sunny afternoons by the pool.
FDA OKs shortcut path for biosimilars
February 15th 2012The Food and Drug Administration has created the first shortcut to the U.S. market for “biosimilar” medicines - cheaper versions of expensive and complex biologic drugs such as infliximab for rheumatoid arthritis, etanercept for plaque psoriasis and psoriatic arthritis, and erythropoietin for anemia.
Off-label treatment with biologics effective for treating certain skin diseases
February 1st 2012Biologic drugs have proven to be of benefit for diseases where there is no indicated treatment, such as for immunobullous diseases. "Pemphigus vulgaris with rituximab (Rituxan, Genentech) has been a major advance, although this is not a formally approved indication for the drug," says Alan Menter, M.D., chief, dermatology, and chairman, residency program, Baylor University Medical Center, Dallas.
Lymphoma diagnosis may be missed without careful evaluation, multiple biopsies
February 1st 2012The cutaneous symptoms of lymphoma and atopic dermatitis (AD) can mimic one another, particularly when AD is severe. An accurate evaluation and assessment of the presenting clinical symptoms is crucial in avoiding a potential misdiagnosis of either disease.
Physicians continue to ponder best decision regarding Medicare participation
February 1st 2012Politicians on Capitol Hill once again have dermatologists - and all physicians who serve Medicare patients - wondering what in the name of common sense they are going to do. Just before Christmas, Congress delayed a 27.4 percent Medicare fee cut from its original Jan. 1 implementation date. The cut is now scheduled, barring any further congressional action, to take effect Feb. 29.
Favorable risk profile for botulinum toxin A supports expanding applications
February 1st 2012Even though botulinum toxin type A is one of the most potent neurotoxins known, its injection into muscles for the reduction of hyperfunctional lines is one of the safest procedures being performed in cosmetic dermatology. And the favorable risk-to-benefit profile of the toxin is fueling its use in an expanding number of off-label applications, says Thomas E. Rohrer, M.D.
Biologic agents relieve chronic skin conditions where other treatments fail
February 1st 2012Biologic therapies can help patients with dermatologic conditions, providing anti-inflammatory benefits without significant effects on other organ systems, says Steven R. Feldman, M.D., Ph.D., professor of dermatology, pathology and public health sciences, Wake Forest Baptist Medical Center, Winston-Salem, N.C.